EBR Systems, Inc. (EBR.AX)
| Previous close | 0.5850 |
| Open | 0.6000 |
| Bid | 0.6000 x N/A |
| Ask | 0.6200 x N/A |
| Day's range | 0.6000 - 0.6050 |
| 52-week range | 0.4200 - 1.3500 |
| Volume | |
| Avg. volume | 88,812 |
| Market cap | 185.717M |
| Beta (5Y monthly) | 1.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1800 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.39 |
- PR Newswire
Positive results from first-in-human completely leadless CRT in the US, published in The Journal of the American College of Cardiology
EBR Systems, Inc. (ASX:EBR), the medical device company developing wireless cardiac pacing systems, is proud to announce that positive results from the first completely leadless cardiac resynchronization therapy (CRT) in the United States have been published in The Journal of American College of Cardiology (JACC).
- PR Newswire
EBR Systems nominated for MTAA Excellence in Medical Technology award
EBR Systems, Inc. (ASX:EBR), the developer of the world's only wireless cardiac pacing device for heart failure, is pleased to announce it has been named as a nominee for the 2023 Medical Technology Association of Australia (MTAA) Kerrin Rennie award.
PR NewswireEBR Systems' Pivotal SOLVE-CRT Trial Meets Endpoints: Excellent Interim Analysis Results Lead to Early Trial Halt for Success
EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchronization Therapy (CRT) System.
